Any current/future new fundraising through debt or equity?

Fredun Pharmaceuticals is currently expanding rapidly and increasing production capacities. They have recently raised funds through a QIP (Qualified Institutional Placement). The company does not foresee any immediate need for additional funds in the next 12 to 18 months. After 18 to 30 months, there might be a possibility of raising funds for new divisions if required. No specific plans or immediate requirements for new fundraising through debt or equity are currently on the table.

Any current/future capex/capital investment/strategic investment?

Fredun Pharmaceuticals is currently expanding production capacities at existing plants and has added new partner manufacturing facilities across various locations (around 37 partner facilities). The company is focused on asset-light manufacturing, especially for new-age products, using third-party manufacturers to leverage cost efficiencies. No immediate requirement for fund-raising or capital infusion is anticipated in the next 12 to 18 months due to internal cash flows and recent fundraise. Potential capital raise might be considered after 18-30 months if required for expansion in different

Future growth expectations in sales/revenue/volumes?

Mobility segment growing at 25% to 30% year-on-year; anticipated further growth with expansion into 4-5 more states, covering nearly 60% of India. New-age business (including mobility, dermaceutics, cosmetics, pet care, nutraceuticals) targeting 20% to 25% annual growth; expected to constitute 51% of total business by 2029-30. Legacy (vintage) business expected to grow at 12% to 18% year-on-year for the next 5-7 years, supported by 1,300-1,400 registrations in the pipeline. Expansion into physiotherapy products and retail outlets ongoing, adding 30-40 outlets per week. Business scaling

Future growth expectations in earnings/operating earnings/profits/EPS?

New-age business is growing at 20-25% year-on-year; vintage (legacy) business expected to grow 12-18% yearly over next 5-7 years. Operational efficiencies in new-age divisions, especially high-margin areas like dermaceutics and pet care, will drive profit growth. Margins currently around 5-6% PAT margin, expected to improve as cost efficiencies kick in over the next 5-7 quarters. Earnings growth expected to have a sudden boost in next 6-7 quarters due to higher-margin new-age products becoming more profitable. By FY 2029-2030, around 51% of revenue expected from new-age business, indic

Current/ Expected Orderbook/ Pending Orders?

Fredun Pharmaceuticals has about 1,300 to 1,400 registrations in the pipeline, which will keep contributing to growth over the next 5 to 7 years. These registrations represent pending orders or approvals that will enable business expansion. The company expects the legacy (vintage) business to grow around 12% to 18% year-on-year, supported by these registrations. New-age business is growing faster at 20% to 25% year-on-year, with multiple product launches and market expansions. Operational scale-up is gradual, launching in new states step-by-step, aiming to cover nearly 60% of India soon. No sp

Fredun Pharmaceuticals LtdQ4 FY26

Fredun Pharmaceuticals Ltd Q4 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,498P/E: 48.9Market Cap: ₹2.2K Cr

Management growth scorecard

Revenue

Category 2

Margin

Category 1

Fundraise

Yes

Order

N/A

Capex

Yes

3 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2

→Mobility segment growing at 25% to 30% year-on-year; anticipated further growth with expansion into 4-5 more states, covering nearly 60% of India.
→New-age business (including mobility, dermaceutics, cosmetics, pet care, nutraceuticals) targeting 20% to 25% annual growth; expected to constitute 51% of total business by 2029-30.
→Legacy (vintage) business expected to grow at 12% to 18% year-on-year for the next 5-7 years, supported by 1,300-1,400 registrations in the pipeline.
→Expansion into physiotherapy products and retail outlets ongoing, adding 30-40 outlets per week.
→Business scaling with a mix of in-house and asset-light manufacturing approaches to support growth.
→Conservative guidance provided aiming for sustainable, robust growth, with operational leverage expected in the next 5-7 quarters.
→Total income showed strong growth of 57% YoY in Q3 FY26 and 48% YoY for 9 months FY26.

Margin guidance

Category 1

→New-age business is growing at 20-25% year-on-year; vintage (legacy) business expected to grow 12-18% yearly over next 5-7 years.
→Operational efficiencies in new-age divisions, especially high-margin areas like dermaceutics and pet care, will drive profit growth.
→Margins currently around 5-6% PAT margin, expected to improve as cost efficiencies kick in over the next 5-7 quarters.
→Earnings growth expected to have a sudden boost in next 6-7 quarters due to higher-margin new-age products becoming more profitable.
→By FY 2029-2030, around 51% of revenue expected from new-age business, indicating a significant growth shift.
→Conservative guidance approach implies potential for overachievement in profits and EPS versus given forecasts.
→Margins and profitability anticipated to sustain and improve with scale and penetration in mobility and other new segments.

3 more insights locked — sign up free to unlock

Fundraise plans

Yes

→Fredun Pharmaceuticals is currently expanding rapidly and increasing production capacities.
→They have recently raised funds through a QIP (Qualified Institutional Placement).
→The company does not foresee any immediate need for additional funds in the next 12 to 18 months.
→After 18 to 30 months, there might be a possibility of raising funds for new divisions if required.
→No specific plans or immediate requirements for new fundraising through debt or equity are currently on the table.

Order book

→Fredun Pharmaceuticals has about 1,300 to 1,400 registrations in the pipeline, which will keep contributing to growth over the next 5 to 7 years.
→These registrations represent pending orders or approvals that will enable business expansion.
→The company expects the legacy (vintage) business to grow around 12% to 18% year-on-year, supported by these registrations.
→New-age business is growing faster at 20% to 25% year-on-year, with multiple product launches and market expansions.
→Operational scale-up is gradual, launching in new states step-by-step, aiming to cover nearly 60% of India soon.
→No specific quantitative orderbook value was disclosed, but the planned registrations and phased launches indicate a healthy and growing order pipeline.

Capex plans

Yes

→Fredun Pharmaceuticals is currently expanding production capacities at existing plants and has added new partner manufacturing facilities across various locations (around 37 partner facilities).
→The company is focused on asset-light manufacturing, especially for new-age products, using third-party manufacturers to leverage cost efficiencies.
→No immediate requirement for fund-raising or capital infusion is anticipated in the next 12 to 18 months due to internal cash flows and recent fundraise.
→Potential capital raise might be considered after 18-30 months if required for expansion in different divisions, but nothing is currently on the table.
→The business is scaling up new-age and legacy segments steadily with phased product launches across states, requiring capital for market penetration but managed through existing resources.

How does Fredun Pharmaceuticals Ltd rank vs peers in ?

Pro feature

1Fredun Pharmaceuticals Ltd

Rev 2Mar 1

See full sector rankings

Want more stocks like Fredun Pharmaceuticals Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio